156 related articles for article (PubMed ID: 38345693)
1. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
Rimini M; Loi E; Rizzato MD; Pressiani T; Vivaldi C; Gusmaroli E; Antonuzzo L; Martinelli E; Garajova I; Giordano G; Lucchetti J; Schirripa M; Cornara N; Rossari F; Vitiello F; Amadeo E; Persano M; Piva VM; Balsano R; Salani F; Pircher C; Cascinu S; Niger M; Fornaro L; Rimassa L; Lonardi S; Scartozzi M; Zavattari P; Casadei-Gardini A
Target Oncol; 2024 Mar; 19(2):223-235. PubMed ID: 38345693
[TBL] [Abstract][Full Text] [Related]
2. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.
Rimini M; Loi E; Fabregat-Franco C; Burgio V; Lonardi S; Niger M; Scartozzi M; Raposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Zavattari P; Casadei-Gardini A
Eur J Cancer; 2022 Nov; 175():299-310. PubMed ID: 36182816
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Oh DY; Lee KH; Lee DW; Yoon J; Kim TY; Bang JH; Nam AR; Oh KS; Kim JM; Lee Y; Guthrie V; McCoon P; Li W; Wu S; Zhang Q; Rebelatto MC; Kim JW
Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):522-532. PubMed ID: 35278356
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab: A Review in Advanced Biliary Tract Cancer.
Fung S; Syed YY
Target Oncol; 2023 Nov; 18(6):965-972. PubMed ID: 37943483
[TBL] [Abstract][Full Text] [Related]
6. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date.
Storandt MH; Jin Z; Mahipal A
Onco Targets Ther; 2024; 17():383-394. PubMed ID: 38774819
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
Rimini M; Fornaro L; Lonardi S; Niger M; Lavacchi D; Pressiani T; Lucchetti J; Giordano G; Pretta A; Tamburini E; Pirrone C; Rapposelli IG; Diana A; Martinelli E; Garajová I; Simionato F; Schirripa M; Formica V; Vivaldi C; Caliman E; Rizzato MD; Zanuso V; Nichetti F; Angotti L; Landriscina M; Scartozzi M; Ramundo M; Pastorino A; Daniele B; Cornara N; Persano M; Gusmaroli E; Cerantola R; Salani F; Ratti F; Aldrighetti L; Cascinu S; Rimassa L; Antonuzzo L; Casadei-Gardini A
Liver Int; 2023 Aug; 43(8):1803-1812. PubMed ID: 37452505
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
Olkus A; Tomczak A; Berger AK; Rauber C; Puchas P; Wehling C; Longerich T; Mehrabi A; Chang DH; Liermann J; Schäfer S; Pfeiffenberger J; Jäger D; Michl P; Springfeld C; Dill MT
Target Oncol; 2024 Mar; 19(2):213-221. PubMed ID: 38416377
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
Ricci AD; D'Alessandro R; Rizzo A; Schirizzi A; Vallarelli S; Ostuni C; Troiani L; Lolli IR; Lotesoriere C; Giannelli G
Immunotherapy; 2023 May; 15(7):477-486. PubMed ID: 36950960
[TBL] [Abstract][Full Text] [Related]
12. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY; He AR; Qin S; Chen LT; Okusaka T; Vogel A; Kim JW; Suksombooncharoen T; Lee MA; Kitano M; Burris H; Bouattour M; Tanasanvimon S; McNamara MG; Zaucha R; Avallone A; Tan B; Cundom J; Lee CK; Takahashi H; Ikeda M; Chen JS; Wang J; Makowsky M; Rokutanda N; Żotkiewicz M; Kurland JF; Cohen G; Valle JW
Future Oncol; 2023 Nov; 19(34):2277-2289. PubMed ID: 37746835
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.
Zhao Q; Xie R; Zhong W; Liu W; Chen T; Qiu X; Yang L
Cost Eff Resour Alloc; 2023 Mar; 21(1):19. PubMed ID: 36859267
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
17. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK; Chon HJ; Cheon J; Lee MA; Im HS; Jang JS; Kim MH; Park S; Kang B; Hong M; Kim JW; Park HS; Kang MJ; Park YN; Choi HJ
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):56-65. PubMed ID: 36328033
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Shroff RT; Javle MM; Xiao L; Kaseb AO; Varadhachary GR; Wolff RA; Raghav KPS; Iwasaki M; Masci P; Ramanathan RK; Ahn DH; Bekaii-Saab TS; Borad MJ
JAMA Oncol; 2019 Jun; 5(6):824-830. PubMed ID: 30998813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
